OpenResearchAlpha

Diabetes, Obesity and Metabolism · 5 Nov 2026

Metformin and Severe Post‐ COVID ‐19 Outcomes Among Individuals With Diabetes Mellitus

Zachary B. Dozierh-index 8, Lin‐Chiun Wang, Yunwen Ji, A. Jerrod Anzalone, Oluwasolape Olawore, Ryan Hafen, Eric Hurwitz, Manav Kumar, Rena C. Patel, Ariana Budhihartanto, Mark van der Laan, John M. Colford, Alan E. Hubbard, John B. Buse, Steven G. Johnson, Jane Reusch, Lauren E. Chan, Richard Moffitt, Rachel Wong, Carolyn Bramante, the National Clinical Cohort Collaborative (N3C) Consortium

0
Citations
no database records one yet
0
Citations in 2026
so far
8
Leading author's h-index
Zachary B. Dozier, in QAI's scholar index
23
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

ABSTRACT Aims We evaluated the relationship between metformin, one of the most commonly prescribed medications for individuals with diabetes, and COVID‐19 sequelae. Materials and Methods We evaluated a retrospective cohort of individuals in the National Clinical Cohort Collaborative with Type 2 diabetes mellitus and COVID‐19 who were prescribed metformin or a dipeptidyl peptidase‐4 inhibitor (DPP4i) at least 30 days before the onset of acute COVID‐19 between 1 October 2021, and 15 November 2023. We compared the 12‐month cumulative incidence of Long COVID diagnosis (ICD‐10 U09.9: Post COVID‐19 condition, unspecified), probable Long COVID (based on a model‐derived phenotype), and mortality between individuals prescribed metformin versus DPP4i. We applied Super Learner and targeted maximum likelihood estimation to obtain risk ratios while adjusting for covariates of interest. Results In our sample of 53 332 individuals with Type 2 diabetes and COVID‐19, we found that metformin prescription was associated with a lower risk of all‐cause mortality after COVID‐19 (adjusted risk ratio [aRR]: 0.61, 95% CI: 0.51, 0.73). We also observed that metformin users, compared to DPP4i users, had a slightly lower risk of probable Long COVID (aRR: 0.87, 95% CI: 0.81, 0.94) but did not detect a significant relationship with the clinically defined outcome of Long COVID diagnosis (aRR: 0.90, 95% CI: 0.68, 1.20). Conclusions These findings support the hypothesis that metformin prescription during acute COVID‐19 may be associated with lower mortality among adults with diabetes.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Zachary B. Dozier has the highest h-index among the authors (8).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (21)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (23)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 3 more references

A free account opens the rest of the citing papers and references on every paper’s page.